Supplement evidence

034 / 575Joint

Glucosamine/chondroitin

View my plan →

The short answer

Some formulations modestly improve osteoarthritis pain for some people.

Evidence and scope: Mixed evidence
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Results vary by product and trial; cartilage regeneration and longevity claims are unsupported.
Before deciding: May interact with warfarin; check shellfish sourcing and glucose concerns.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Joint symptoms1,500 mg/day crystalline glucosamine sulfate in many osteoarthritis trials

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityWater-soluble

Water-soluble or readily water-dispersible. This does not mean excess is always harmless.

How it is commonly taken

Take with food if GI symptoms occur.

Do not combine casually

Warfarin interaction is important; shellfish source, diabetes, and product form require review.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

5research papers in this ledger

25unique primary studies represented

4,963unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2020

Evidence contextPMID 32253185

Association of habitual glucosamine use with risk of cardiovascular disease and mortality

Habitual users had lower adjusted cardiovascular and mortality risks, but healthier-user behavior, residual confounding, and exposure misclassification prevent a treatment-effect conclusion.

Published: 2020Duration: Median 8.9 yearsn=495,077 participants

Study design and methods

Design: Prospective observational UK Biobank cohort
Population: 495,077 adults without cardiovascular disease at baseline
Intervention: Self-reported habitual glucosamine use; no randomized treatment
Outcome: Cardiovascular events and mortality

Open research record ↗

2008

Safety signalPMID 18363538

Potential glucosamine-warfarin interaction resulting in increased international normalized ratio

Dose increases were followed by higher INR in the detailed case, and spontaneous reports included bleeding. These reports cannot estimate incidence or prove causality, but they support INR monitoring and clinician review when warfarin users start or change glucosamine.

Published: 2008

Study design and methods

Design: Case report plus FDA MedWatch and WHO spontaneous-report review
Population: One detailed patient, 20 FDA reports, and 21 WHO reports involving warfarin or related anticoagulants
Intervention: Glucosamine, often with chondroitin, during anticoagulant therapy
Outcome: Raised INR and bleeding reports

Open research record ↗

2006

Does not support the tested claimPMID 16495392 · NCT00032890

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

Glucosamine alone and the glucosamine–chondroitin combination were not superior to placebo overall. A positive moderate-to-severe-pain subgroup result was exploratory and based on a small subgroup.

Published: 2006Duration: 24 weeksn=1,583 participants

Study design and methods

Design: NIH-sponsored multicenter randomized, double-blind trial
Population: 1,583 adults with symptomatic knee osteoarthritis
Intervention: Glucosamine hydrochloride, chondroitin, their combination, celecoxib, or placebo
Outcome: At least 20% reduction in knee pain

Funding or conflict note: Already represented in the Cochrane trial collection; displayed separately because it clarifies hydrochloride and combination claims.

Open research record ↗

2005

Mixed or qualifiedPMID 15846645

Glucosamine therapy for treating osteoarthritis

Pooled results suggested small benefits, but adequately concealed trials and non-Rotta products showed no pain or WOMAC benefit. Positive findings were concentrated in one manufacturer-specific crystalline sulfate product, so products are not interchangeable.

Published: 2005n=4,963 participants25 primary studies represented

Study design and methods

Design: Cochrane systematic review of 25 randomized trials
Population: 4,963 adults with osteoarthritis, mostly knee osteoarthritis
Intervention: Glucosamine products versus placebo or active comparators
Outcome: Pain, function, WOMAC scores, and structural progression

Open research record ↗

2002

Supports a specific usePMID 12374520

Glucosamine sulfate use and delay of progression of knee osteoarthritis

The named crystalline sulfate product reduced radiographic joint-space loss and improved symptoms, but the result is formulation- and manufacturer-specific and is already represented in the Cochrane review.

Published: 2002Duration: 3 yearsn=202 participants

Study design and methods

Design: Randomized, double-blind, placebo-controlled trial
Population: 202 adults with knee osteoarthritis
Intervention: Prescription crystalline glucosamine sulfate 1,500 mg/day or placebo
Outcome: Joint-space narrowing and symptoms

Funding or conflict note: The tested crystalline sulfate formulation was developed by the Rotta/Rottapharm group, which is central to the product-specific evidence boundary.

Open research record ↗

Unscreened discovery appendix—not evidence328 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewNational Center for Complementary and Integrative Health Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.